Werner Scheithauer
Overview
Explore the profile of Werner Scheithauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
7224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al.
J Clin Oncol
. 2023 Jul;
41(21):3663-3669.
PMID: 37459755
Purpose: To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic...
2.
Hofmann F, Heinemann V, DAnastasi M, Gesenhues A, Hesse N, Fischer von Weikersthal L, et al.
Eur Radiol
. 2022 Aug;
33(2):1174-1184.
PMID: 35976398
Objectives: Early tumor shrinkage (ETS) quantifies the objective response at the first assessment during systemic treatment. In metastatic colorectal cancer (mCRC), ETS gains relevance as an early available surrogate for...
3.
Fischer L, Stintzing S, Fischer von Weikersthal L, Modest D, Decker T, Kiani A, et al.
Br J Cancer
. 2022 May;
127(5):836-843.
PMID: 35637412
Background: The evidence on the efficacy of anticancer therapy is limited in older patients with metastatic colorectal cancer (mCRC). This retrospective analysis of phase III FIRE-3 trial assesses the efficacy...
4.
Stahler A, Stintzing S, von Einem J, Westphalen Benedikt C, Heinrich K, Kramer N, et al.
Eur J Cancer
. 2022 May;
169:223-225.
PMID: 35570084
No abstract available.
5.
Liu L, Erickson N, Ricard I, Fischer von Weikersthal L, Lerch M, Decker T, et al.
Int J Cancer
. 2021 Aug;
150(1):112-123.
PMID: 34431518
Body weight loss is frequently regarded as negatively related to outcomes in patients with malignancies. This retrospective analysis of the FIRE-3 study evaluated the evolution of body weight in patients...
6.
Sobrero A, Lenz H, Eng C, Scheithauer W, Middleton G, Chen W, et al.
Oncologist
. 2020 Nov;
26(2):e261-e269.
PMID: 33191588
Background: The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with epidermal growth factor receptor-detectable metastatic colorectal cancer (mCRC) that progressed...
7.
Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Al-Batran S, et al.
Br J Cancer
. 2020 Nov;
124(3):587-594.
PMID: 33154570
Background: Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no corresponding benefit was found for progression-free survival....
8.
Bianconi D, Herac M, Posch F, Schmeidl M, Unseld M, Kieler M, et al.
Ther Adv Med Oncol
. 2020 Sep;
12:1758835920928635.
PMID: 32922518
Background: Targeted therapies offer novel opportunities to explore biomarkers based on their mode of action. Taking this into consideration, we evaluated six angiogenesis-related proteins as potential predictive biomarkers, which expression...
9.
Stahler A, Stintzing S, von Einem J, Westphalen C, Heinrich K, Kramer N, et al.
Eur J Cancer
. 2020 Aug;
137:250-259.
PMID: 32810748
Background: Molecular biomarkers and primary tumour sidedness guide treatment decisions in metastatic colorectal cancer. Comprehensive molecular profiling aims to identify targetable alterations and measure tumour mutational burden (TMB) to enable...
10.
Schulz C, Heinemann V, Heinrich K, Haas M, Holch J, Fraccaroli A, et al.
Anticancer Drugs
. 2020 Jul;
31(8):856-865.
PMID: 32639280
Magnesium wasting is a frequent side effect of epidermal growth factor receptor (EGFR)-antibody treatment as magnesium-absorption mechanisms are dependent on EGFR signaling. EGFR-inhibition results in decreased renal reabsorption. There is...